









Markets
/
Stocks
/
nasdaq-zlab
/

Zai Lab Ltd

ZLAB



View Detailed Chart

18.330USD

-0.250-1.35%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

2.03BMarket Cap

LossP/E TTM



Zai Lab Ltd

18.330

-0.250-1.35%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.35%

5 Days

+1.61%

1 Month

-8.21%

6 Months

-49.35%

Year to Date

-30.01%

1 Year

-32.66%

View Detailed Chart

TradingKey Stock Score of Zai Lab Ltd

Currency: USD Updated: 2025-12-26

Key Insights

Zai Lab Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.85.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zai Lab Ltd's Score

Industry at a Glance

Industry Ranking

72 / 158

Overall Ranking

181 / 4563

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

47.852

Target Price

+151.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Zai Lab Ltd Highlights

StrengthsRisks

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 85.54% year-on-year.

Fairly Valued

The company’s latest PE is -9.40, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.61M shares, decreasing 24.80% quarter-over-quarter.

Held by Sarah Ketterer

Star Investor Sarah Ketterer holds 50.91K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.33.